1351890267-1144543684.jpg

FDA New Drug and Biologic Approvals, 2018 Midyear Review

In This Issue 

The FDA New Drug and Biologic Approvals, 2018 Midyear Review describes new molecular entities, new biologics, and select new indications by condition for those drugs and biologics approved during the first half of this year. Each summary contains information on the indication, mechanism, dosage, and clinical trials that served as the basis for the FDA approval. For more information, each drug or biologic is linked to its corresponding Medscape drug monograph.

Primary Care

Hematology/Oncology

Infectious Disease

Neurology

Pediatrics

 

 

 

arrow
arrow
    文章標籤
    新藥 FDA Approvals
    全站熱搜

    快樂小藥師 發表在 痞客邦 留言(0) 人氣()